Revive Therapeutics closes first tranche of private placement

Revive Therapeutics Ltd. (OTCQB: RVVTF)(CSE: RVV) closed the first tranche of a non-brokered private placement, raising gross proceeds of $246,920, according to a press release dated July 15, 2026.

The placement involved the issuance of 7,716,250 units at $0.032 per unit. Each unit consists of one common share and one warrant, with each warrant exercisable at $0.05 per share for 36 months from the closing date.

The company said it intends to use the proceeds primarily for working capital purposes.

In connection with the closing, Revive paid finders fees totaling $17,433.60 and issued 537,300 broker warrants, each exercisable at $0.05 per common share for a period of 36 months. All securities issued are subject to a hold period of four months and one day from the date of issuance.

The company said it will provide updates on any further closings under the private placement.

You May Also Be Interested In

• Goldman Sachs Starts Excelerate Energy Inc (EE) at Buy
• Goldman Sachs Starts NextDecade Corp. (NEXT) at Neutral
• Rakovina Therapeutics plans $1.5M private placement